Table 5.
The relationship between markers of bone turnover and osteoclastogenesis markers as well as PINP/CTX-I, sRANKL/OPG ratios, and clinical and laboratory indicators of disease activity in women with rheumatoid arthritis at the baseline and after 15 months of anti-TNF-α therapy.
Parameter | RA Patients (n = 31) Time after Initiation of TNFαI Therapy |
|||||
---|---|---|---|---|---|---|
Baseline (T0) | ||||||
PINP | CTX-I | PINP/CTX-I | sRANKL | OPG | sRANKL/OPG | |
CRP | −0.167 NS | −0.216 NS | 0.03 NS | 0.238 NS | −0.05 NS | 0.302 NS |
ESR | 0.044 NS | −0.075 NS | 0.213 NS | 0.247 NS | 0.233 NS | 0.176 NS |
DAS28-ESR | 0.012 NS | −0.216 NS | 0.132 NS | −0.221 NS | 0.07 NS | −0.207 NS |
SJC | −0.130 NS | −0.223 NS | 0.068 NS | −0.307 NS | 0.001 NS | −0.305 NS |
TJC | −0.027 NS | 0.0245 NS | −0.088 NS | −0.044 NS | −0.236 NS | −0.320 NS |
VAS | 0.105 NS | 0.146 NS | −0.097 NS | −0.047 NS | 0.101 NS | −0.160 NS |
15 Months (T3) | ||||||
CRP | −0.08 NS | 0.319 NS | −0.333 NS | −0.03 NS | −0.128 NS | 0.059 NS |
ESR | 0.202 NS | 0.067 NS | 0.145 NS | 0.169 NS | 0.285 NS | 0.091 NS |
DAS28-ESR | 0.185 NS | 0.112 NS | 0.054 NS | 0.193 NS | 0.255 NS | 0.077 NS |
SJC | 0.353 NS | 0.085 NS | 0.097 NS | 0.000 NS | −0.036 NS | 0.012 NS |
TJC | −0.028 NS | −0.028 NS | 0.0176 NS | 0.097 NS | −0.214 NS | 0.051 NS |
VAS | 0.082 NS | 0.040 NS | −0.047 NS | 0.071 NS | 0.322 NS | −0.091 NS |
Results are expressed as r (correlation coefficient) according to Spearman rank correlation. Correlations were considered significant at: p < 0.0083 by applying a Bonferroni correction. DAS 28-ESR, disease activity score 28; CTX-I, C-terminal cross-linking telopeptides of type I collagen; ESR, erythrocyte sedimentation rate; NS, not significant; OPG, osteoprotegerin; PINP, N-terminal propeptides of type I procollagen; RA, rheumatoid arthritis; SJC, swollen joint count; sRANKL, total soluble receptor activator of nuclear factor κB ligand; TJC, tender joint count; TNFαΙ, tumor necrosis factor α inhibitors.